(Q38773523)

6 September 2017

title

Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment (English)

1 reference

mild cognitive impairment

6 September 2017

0 references

0 references

1 reference

11

Johannes Kornhuber

1 reference

6 September 2017

4

Luca Kleineidam

1 reference

6 September 2017

10

Wolfgang Maier

1 reference

6 September 2017

13

Frank Jessen

1 reference

6 September 2017

1

Steffen Wolfsgruber

1 reference

6 September 2017

Jens Wiltfang

9

0 references

Michael Wagner

object named as

Michael Wagner

Olive Melissa Minor Peters

14

0 references

6

object named as

Oliver Peters

1 reference

6 September 2017

12

Piotr Lewczuk

1 reference

6 September 2017

5

Lutz Frölich

1 reference

6 September 2017

7

Michael Hüll

1 reference

6 September 2017

Alexandra Polcher

2

1 reference

6 September 2017

Alexander Koppara

3

1 reference

6 September 2017

Eckart Rüther

8

1 reference

6 September 2017

language of work or name

1 reference

13 May 2017

1 reference

Journal of Alzheimer's Disease

6 September 2017

published in

1 reference

6 September 2017

volume

58

1 reference

6 September 2017

issue

3

1 reference

6 September 2017

page(s)

939-950

1 reference

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3233%2FJAD-161252

A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-161252

Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-161252

Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-161252

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-161252

High Prevalence of Stress and Low Prevalence of Alzheimer Disease CSF Biomarkers in a Clinical Sample with Subjective Cognitive Impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-161252

Preclinical AD predicts decline in memory and executive functions in subjective complaints

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-161252

Mild cognitive impairment: clinical characterization and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-161252

Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-161252

Considering the base rates of low performance in cognitively healthy older adults improves the accuracy to identify neurocognitive impairment with the Consortium to Establish a Registry for Alzheimer's Disease-Neuropsychological Assessment Battery (

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-161252

Implementation of subjective cognitive decline criteria in research studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-161252

Early and differential diagnosis of dementia and mild cognitive impairment: design and cohort baseline characteristics of the German Dementia Competence Network

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-161252

The German Competence Net Dementias: standard operating procedures for the neurochemical dementia diagnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-161252

The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean?

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-161252

Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-161252

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-161252

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-161252

Differentiating moderate and severe depression using the Montgomery-Asberg depression rating scale (MADRS).

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-161252

The Bayer Activities of Daily Living Scale (B-ADL).

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-161252

Comparison of imaging biomarkers in the Alzheimer Disease Neuroimaging Initiative and the Mayo Clinic Study of Aging

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-161252

AD dementia risk in late MCI, in early MCI, and in subjective memory impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-161252

Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-161252

Amyloid Pathology, Cognitive Impairment, and Alzheimer Disease Risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-161252

Subjective cognitive decline in cognitively normal elders from the community or from a memory clinic: Differential affective and imaging correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-161252

Mild cognitive impairment as a diagnostic entity

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-161252

Validation of the Erlangen Score Algorithm for the Prediction of the Development of Dementia due to Alzheimer's Disease in Pre-Dementia Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-161252

Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-161252

Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-161252

A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-161252

Cerebrospinal Fluid Biomarkers Predict Clinical Evolution in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-161252

21 January 2018

Identifiers

DOI

10.3233/JAD-161252

1 reference

6 September 2017

1 reference